Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12


A coiled-coil masking domain for selective activation of therapeutic antibodies.

Trang VH, Zhang X, Yumul RC, Zeng W, Stone IJ, Wo SW, Dominguez MM, Cochran JH, Simmons JK, Ryan MC, Lyon RP, Senter PD, Levengood MR.

Nat Biotechnol. 2019 Jul;37(7):761-765. doi: 10.1038/s41587-019-0135-x. Epub 2019 May 27.


Characterization of SGN-CD123A, A Potent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid Leukemia.

Li F, Sutherland MK, Yu C, Walter RB, Westendorf L, Valliere-Douglass J, Pan L, Cronkite A, Sussman D, Klussman K, Ulrich M, Anderson ME, Stone IJ, Zeng W, Jonas M, Lewis TS, Goswami M, Wang SA, Senter PD, Law CL, Feldman EJ, Benjamin DR.

Mol Cancer Ther. 2018 Feb;17(2):554-564. doi: 10.1158/1535-7163.MCT-17-0742. Epub 2017 Nov 15.


Tumor-Associated Macrophages Can Contribute to Antitumor Activity through FcγR-Mediated Processing of Antibody-Drug Conjugates.

Li F, Ulrich M, Jonas M, Stone IJ, Linares G, Zhang X, Westendorf L, Benjamin DR, Law CL.

Mol Cancer Ther. 2017 Jul;16(7):1347-1354. doi: 10.1158/1535-7163.MCT-17-0019. Epub 2017 Mar 24.


Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates.

Burke PJ, Hamilton JZ, Jeffrey SC, Hunter JH, Doronina SO, Okeley NM, Miyamoto JB, Anderson ME, Stone IJ, Ulrich ML, Simmons JK, McKinney EE, Senter PD, Lyon RP.

Mol Cancer Ther. 2017 Jan;16(1):116-123. doi: 10.1158/1535-7163.MCT-16-0343. Epub 2016 Nov 9.


Development of Novel Quaternary Ammonium Linkers for Antibody-Drug Conjugates.

Burke PJ, Hamilton JZ, Pires TA, Setter JR, Hunter JH, Cochran JH, Waight AB, Gordon KA, Toki BE, Emmerton KK, Zeng W, Stone IJ, Senter PD, Lyon RP, Jeffrey SC.

Mol Cancer Ther. 2016 May;15(5):938-45. doi: 10.1158/1535-7163.MCT-16-0038. Epub 2016 Mar 4.


A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology.

Jeffrey SC, Burke PJ, Lyon RP, Meyer DW, Sussman D, Anderson M, Hunter JH, Leiske CI, Miyamoto JB, Nicholas ND, Okeley NM, Sanderson RJ, Stone IJ, Zeng W, Gregson SJ, Masterson L, Tiberghien AC, Howard PW, Thurston DE, Law CL, Senter PD.

Bioconjug Chem. 2013 Jul 17;24(7):1256-63. doi: 10.1021/bc400217g. Epub 2013 Jun 28.


Proapoptotic signaling activity of the anti-CD40 monoclonal antibody dacetuzumab circumvents multiple oncogenic transformation events and chemosensitizes NHL cells.

Lewis TS, McCormick RS, Stone IJ, Emmerton K, Mbow B, Miyamoto J, Drachman JG, Grewal IS, Law CL.

Leukemia. 2011 Jun;25(6):1007-16. doi: 10.1038/leu.2011.21. Epub 2011 Mar 11.


Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40.

Oflazoglu E, Stone IJ, Brown L, Gordon KA, van Rooijen N, Jonas M, Law CL, Grewal IS, Gerber HP.

Br J Cancer. 2009 Jan 13;100(1):113-7. doi: 10.1038/sj.bjc.6604812. Epub 2008 Dec 9.


Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker.

Oflazoglu E, Stone IJ, Gordon K, Wood CG, Repasky EA, Grewal IS, Law CL, Gerber HP.

Clin Cancer Res. 2008 Oct 1;14(19):6171-80. doi: 10.1158/1078-0432.CCR-08-0916. Epub 2008 Sep 22.


Effects of dehydroepiandrosterone sulfate and progesterone on spatial learning and memory in young and aged mice.

Bodensteiner KJ, Stone IJ, Ghiraldi LL.

J Gen Psychol. 2008 Jul;135(3):271-86. doi: 10.3200/GENP.135.3.271-286.


Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30.

Oflazoglu E, Stone IJ, Gordon KA, Grewal IS, van Rooijen N, Law CL, Gerber HP.

Blood. 2007 Dec 15;110(13):4370-2. Epub 2007 Oct 1.


Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates.

Jeffrey SC, Andreyka JB, Bernhardt SX, Kissler KM, Kline T, Lenox JS, Moser RF, Nguyen MT, Okeley NM, Stone IJ, Zhang X, Senter PD.

Bioconjug Chem. 2006 May-Jun;17(3):831-40.


Supplemental Content

Loading ...
Support Center